Gender susceptibility to COVID-19: a review of the putative role of sex hormones and X chromosome.


Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
May 2021
Historique:
received: 09 06 2020
accepted: 31 07 2020
pubmed: 17 9 2020
medline: 23 4 2021
entrez: 16 9 2020
Statut: ppublish

Résumé

The recent emergence of COVID-19 poses a global health emergency. One of the most frequently reported data is sex-related severity and mortality: according to the last available analysis on 239,709 patients in Italy, lethality is 17.7% in men and 10.8% in women, with 59% of total deaths being men. Interestingly, the infection rate is lower in males than in females, with 45.8% and 54.2% of positive cases, respectively, suggesting that gender-related factor may worsen disease evolution. A tentative hypothesis to explain these findings is the role of angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 involved in viral infection. In this review, we summarize the available evidence pointing to gender-related differences in ACE2 and TMPRSS2 expression, from both genetic and endocrine points of view. Altogether, available evidence points toward two not-mutually exclusive mechanisms in gender susceptibility to COVID-19 by sex hormonal regulation of ACE2 and TMPRSS2. On one hand, ACE2 expression could be increased in women, either by estrogens or constitutively by X chromosome inactivation escape or by reduced methylation, providing a larger reservoir of ACE2 to maintain the fundamental equilibrium of RAS regulatory axis. On the other, low levels of androgens in women may keep at low levels TMPRSS2 expression, representing a further protective factor for the development of COVID-19 infection, despite the increased expression of ACE2, which represents the Trojan horse for SARS-CoV-2 entry. Both mechanisms consistently point to the role of sex hormones and sex chromosomes in the differential severity and lethality of COVID-19 in men and women.

Sections du résumé

BACKGROUND BACKGROUND
The recent emergence of COVID-19 poses a global health emergency. One of the most frequently reported data is sex-related severity and mortality: according to the last available analysis on 239,709 patients in Italy, lethality is 17.7% in men and 10.8% in women, with 59% of total deaths being men. Interestingly, the infection rate is lower in males than in females, with 45.8% and 54.2% of positive cases, respectively, suggesting that gender-related factor may worsen disease evolution. A tentative hypothesis to explain these findings is the role of angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 involved in viral infection.
PURPOSE OBJECTIVE
In this review, we summarize the available evidence pointing to gender-related differences in ACE2 and TMPRSS2 expression, from both genetic and endocrine points of view.
RESULTS RESULTS
Altogether, available evidence points toward two not-mutually exclusive mechanisms in gender susceptibility to COVID-19 by sex hormonal regulation of ACE2 and TMPRSS2. On one hand, ACE2 expression could be increased in women, either by estrogens or constitutively by X chromosome inactivation escape or by reduced methylation, providing a larger reservoir of ACE2 to maintain the fundamental equilibrium of RAS regulatory axis. On the other, low levels of androgens in women may keep at low levels TMPRSS2 expression, representing a further protective factor for the development of COVID-19 infection, despite the increased expression of ACE2, which represents the Trojan horse for SARS-CoV-2 entry.
CONCLUSIONS CONCLUSIONS
Both mechanisms consistently point to the role of sex hormones and sex chromosomes in the differential severity and lethality of COVID-19 in men and women.

Identifiants

pubmed: 32936429
doi: 10.1007/s40618-020-01383-6
pii: 10.1007/s40618-020-01383-6
pmc: PMC7492232
doi:

Substances chimiques

Gonadal Steroid Hormones 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Serine Endopeptidases EC 3.4.21.-
TMPRSS2 protein, human EC 3.4.21.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

951-956

Références

PLoS One. 2015 May 26;10(5):e0127515
pubmed: 26010093
J Endocrinol Invest. 2020 Aug;43(8):1153-1157
pubmed: 32462316
Front Cell Dev Biol. 2019 Oct 22;7:241
pubmed: 31696116
Ann Oncol. 2020 Aug;31(8):1040-1045
pubmed: 32387456
J Virol. 2009 Apr;83(7):3200-11
pubmed: 19158246
Nature. 1961 Apr 22;190:372-3
pubmed: 13764598
Mol Med Rep. 2017 Jun;15(6):3905-3911
pubmed: 28440441
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
PLoS One. 2012;7(4):e35876
pubmed: 22558251
Ann Intern Med. 2003 Nov 4;139(9):715-23
pubmed: 14597455
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Biol Reprod. 2020 Jun 23;103(1):4-6
pubmed: 32297920
J Hypertens. 2012 Feb;30(2):375-83
pubmed: 22179088
Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1392-9
pubmed: 22460555
Nature. 2017 Oct 11;550(7675):244-248
pubmed: 29022598
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Endocrinol Invest. 2020 Dec;43(12):1819-1822
pubmed: 32329026
Nat Commun. 2014 May 06;5:3594
pubmed: 24800825
Cancer Res. 1999 Sep 1;59(17):4180-4
pubmed: 10485450
Exp Biol Med (Maywood). 2017 Aug;242(14):1412-1423
pubmed: 28661206
Int J Infect Dis. 2020 Apr;93:264-267
pubmed: 32114193
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235486
Life Sci. 2006 Apr 4;78(19):2166-71
pubmed: 16303146
Andrology. 2021 Jan;9(1):27-29
pubmed: 32452644
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Endocrinology. 2004 Oct;145(10):4703-11
pubmed: 15231706
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Aging Cell. 2020 Jul;19(7):
pubmed: 32558150
Hum Genet. 2011 Aug;130(2):237-45
pubmed: 21614513
Cancer Discov. 2020 Jun;10(6):779-782
pubmed: 32276929
J Virol. 2010 Dec;84(24):12658-64
pubmed: 20926566
Andrology. 2021 Jan;9(1):23-26
pubmed: 32453494
Andrology. 2021 Jan;9(1):88-98
pubmed: 32436355
Drug Dev Res. 2020 Aug;81(5):537-540
pubmed: 32129518
Hum Mol Genet. 2001 Oct 1;10(20):2225-32
pubmed: 11673405
Biochim Biophys Acta. 1984 Sep 10;782(4):331-42
pubmed: 6383476
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Chin Med J (Engl). 2020 May 5;133(9):1039-1043
pubmed: 32118639

Auteurs

C Foresta (C)

Department of Medicine, Unit of Andrology and Medicine of Human Reproduction, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy. carlo.foresta@unipd.it.

M S Rocca (MS)

Department of Medicine, Unit of Andrology and Medicine of Human Reproduction, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.

A Di Nisio (A)

Department of Medicine, Unit of Andrology and Medicine of Human Reproduction, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH